Quarterly Report I 23/24

September 2023 – November 2023, Diamyd Medical AB (publ), Fiscal year 2023/2024Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2023 – November 30, 2023 · Operating income: MSEK 1.0 (1.0) · Net result: MSEK -32.8 (-33.0) · Result per share: SEK -0.4 (-0.4) · Cash flow from operating activities: MSEK -27.8 (-27.1) · Cash and short-term investments at November 30, 2023: MSEK 176.7 (130.9)